Blog

Nuclear fusion has long held the promise of cheap, plentiful and, above all, clean energy with zero carbon emissions and minimal radiation issues that undermine public confidence in nuclear fission. The UK has been at the forefront of fusion research, hosting the Joint European Torus (JET) at the UK Atomic Energy Authority’s (UKAEA) site at […]

read more

UKI2S biotech company CellCentric, University of Cambridge spinout, has raised $26m to fund clinical testing of its first-in-class oncology drug candidate, CCS1477. CellCentric focuses on treating prostate cancer, as well as multiple other cancers. Their new drug candidate addresses the large and increasing population of patients – upwards of 80,000 people each year — who […]

read more

UK Innovation & Science Seed Fund  is a patient capital investor in ideas emerging from the UK’s publicly-funded science base. We are now collaborating with the Innovate UK’s Catapult Network. In recognition of our widening scope, ambition and remit, from the start of 2018, UKI2S will be renamed UK Innovation & Science Seed Fund (UKI2S). […]

read more

1 2 3 5